文献速递乳腺癌

高危早期乳腺癌的定制剂量密集方案对比标准辅助化疗:随机PANTHER试验的研究结束结果

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
PubMed 文献 · J Clin Oncol · 2024-07-17

PANTHER是一项国际III期试验,比较序贯表柔比星/环磷酰胺和紫杉醇或多西他赛每2周或每3周给药,剂量密集方案根据血液学毒性定制剂量。中位随访10.3年,剂量密集治疗较标准辅助化疗改善乳腺癌无复发生存(HR 0.80,95%CI 0.65-0.98,P=0.030)、无事件生存(HR 0.78,95%CI 0.65-0.94,P=0.009)和远处无病生存(HR 0.79,95%CI 0.64-0.98,P=0.030),总生存改善无统计学显著性(HR 0.82,95%CI 0.65-1.04,P=0.109)。

要点

  • 中位随访10.3年,剂量密集方案较标准辅助化疗改善乳腺癌无复发生存、无事件生存和远处无病生存。
  • 总生存改善无统计学显著性(HR 0.82,95%CI 0.65-1.04,P=0.109)。
  • 这是首个证实剂量密集方案优于含多西他赛每3周对照方案的试验。

核心结论

  • 与标准辅助化疗相比,剂量密集治疗改善乳腺癌无复发生存、无事件生存和远处无病生存,总生存改善无统计学显著性。
  • 据作者所知,这是首个证实剂量密集方案优于含多西他赛每3周对照方案的试验。

研究设计与样本

  • PANTHER是一项国际III期随机试验。
  • 比较序贯表柔比星/环磷酰胺和紫杉醇或多西他赛每2周或每3周给药,剂量密集方案根据血液学毒性定制剂量。
  • 本分析为研究结束分析,中位随访10.3年。

主要发现

  • 剂量密集治疗对比标准辅助化疗:乳腺癌无复发生存HR 0.80(95%CI 0.65-0.98;P=0.030)。
  • 剂量密集治疗对比标准辅助化疗:无事件生存HR 0.78(95%CI 0.65-0.94;P=0.009)。
  • 剂量密集治疗对比标准辅助化疗:远处无病生存HR 0.79(95%CI 0.64-0.98;P=0.030)。
  • 剂量密集治疗对比标准辅助化疗:总生存HR 0.82(95%CI 0.65-1.04;P=0.109),改善无统计学显著性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Although dose-dense adjuvant chemotherapy administered once every 2 weeks leads to superior outcomes compared with standard regimens once every 3 weeks, the observed improvement is largely limited to studies using the suboptimal paclitaxel schedule once every 3 weeks as control. PANTHER is an international phase III trial which compared sequential epirubicin/cyclophosphamide and docetaxel administered either once every 2 or once every 3 weeks, with tailored dosing at the dose-dense schedule according to hematologic toxicity. In this end-of-study analysis, the median follow-up was 10.3 years. Compared with standard adjuvant chemotherapy, dose-dense treatment improved breast cancer recurrence-free survival (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.98]; P = .030), event-free survival (HR, 0.78 [95% CI, 0.65 to 0.94]; P = .009), and distant disease-free survival (HR, 0.79 [95% CI, 0.64 to 0.98]; P = .030) while the improvement in overall survival was not statistically significant (HR, 0.82 [95% CI, 0.65 to 1.04]; P = .109). To our knowledge, this is the first trial that confirms the benefit of a dose-dense regimen over a control regimen containing docetaxel once every 3 weeks.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Matikas A, Möbus V, Greil R, et al. Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial. J Clin Oncol. 2024. PMID: 39018515. doi:10.1200/JCO.24.00178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。